2-(2,3-Dicarboxycyclopropyl)glycine | 147782-19-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(2,3-Dicarboxycyclopropyl)glycine
• 英文别名: (1R)-3-[(S)-amino(carboxy)methyl]cyclopropane-1,2-dicarboxylic acid
• CAS: 147782-19-2
• 化学式: C₇H₉NO₆
• 分子量: 203.15
• InChiKey: MATPZHBYOVDBLI-IDPZHQIBSA-N

物化性质

• 沸点：
  503.9±40.0 °C(Predicted)
• 密度：
  1.819±0.06 g/cm3(Predicted)
• 溶解度：
  可微溶于水
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  -4.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  138
• 氢给体数：
  4
• 氢受体数：
  7

制备方法与用途

生物活性 DCG-IV 是一种有效的 II 类 mGluRs 受体激动剂，对 mGlu2R 和 mGlu3R 的 EC50 值分别为 0.35 μM 和 0.09 μM。同时，它也是 I 组 (IC50: mGlu1R/5R=389/630 μM) 和 III 组受体 (IC50: mGlu4R/6R/7R/8R=22.5/39.6/40.1/32 μM) 的竞争性拮抗剂。DCG-IV 具有抗惊厥和神经保护作用。

靶点

受体	EC50/IC50 (μM)
mGluR2	0.35
mGluR3	0.09
mGluR1	389
mGluR5	630
mGluR4	22.5
mGluR6	39.6
mGluR7	40.1
mGluR8	32

体外研究

DCG-IV 还是大鼠皮层切片中的 NMDA 受体激动剂。

体内研究

DCG-IV (1-10 mg/kg, i.p.) 能抑制 PCP 引起的过度活动。具体实验数据如下：

实验条件	内容
动物模型	雄性 ICR 小鼠，体重约 40 g
剂量	10 mg/kg, 5 mg/kg, 或 1 mg/kg
给药途径	腹腔注射 (i.p.)
实验结果	在 10 mg/kg 和 5 mg/kg 下，小鼠自发活动减少。

文献信息

• Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
  申请人：Prescient NeuroPharma Inc.

  公开号：US20040147482A1

  公开（公告）日：2004-07-29

  Thee present invention relates to therapeutically active cubane compounds, a method of preparing the same, and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in creating diseases of the central nervous system related to the metabotropic glutamate receptor system.

  该发明涉及治疗活性的立方烷化合物，一种制备方法，以及包含这些化合物的药物组合物。这些新型化合物可用于治疗与代谢型谷氨酸受体系统相关的中枢神经系统疾病。
• Glutamate receptor modulators and therapeutic agents
  申请人：Wood Richard Delarey

  公开号：US20090239919A1

  公开（公告）日：2009-09-24

  The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds. Diseases and disorders contemplated include, inter alia, diseases and disorders of the central nervous system, the peripheral nervous system, the gastrointestinal system, the circulatory system, skin, retina, brain, heart, and lungs.

  本发明公开了利用一类明确定义的苯甲酰胺化合物调节I类mGluRs活性的方法。在一个实施例中，提供了调节mGluR1活性的方法。在另一个实施例中，提供了调节mGluR5活性的方法。在另一个实施例中，提供了同时调节mGluR1和mGluR5活性的方法。本发明还提供了利用属于明确定定义的苯甲酰胺化合物类的一个或多个化合物治疗由I类mGluRs完全或部分介导的疾病或紊乱的方法。本发明还提供了利用属于明确定定义的化合物类的一个或多个化合物预防由I类mGluRs完全或部分介导的疾病或紊乱的方法。所考虑的疾病和紊乱包括中枢神经系统、外周神经系统、胃肠系统、循环系统、皮肤、视网膜、大脑、心脏和肺等疾病和紊乱。
• Novel spiro[2.4]heptane amino carboxy compounds and derivatives thereof
  申请人：——

  公开号：US20040077599A1

  公开（公告）日：2004-04-22

  The present invention relates to therapeutically active novel spiro[2,4]heptane amino carboxy compounds and derivatives thereof. Also provided is a method of preparing compounds of Formula (I), and pharmaceutical compositions comprising the compounds. The novel compounds act as modulators of metabotropic glutamate receptors and, as such, are useful in treating diseases of the central nervous system related to the metabotropic glutamate receptor system. 1

  本发明涉及治疗活性新的螺[2,4]庚烷氨基羧化合物及其衍生物。还提供了制备式(I)化合物的方法和包含该化合物的药物组合物。这些新的化合物作为代谢型谷氨酸受体的调节剂，因此在治疗与代谢型谷氨酸受体系统相关的中枢神经系统疾病方面是有用的。
• Novel amino carboxy alkyl derivatives of barbituric acid
  申请人：——

  公开号：US20030199533A1

  公开（公告）日：2003-10-23

  The present invention relates to therapeutically active novel amino, carboxy, alkyl derivatives of barbituric acid of Formula (I), wherein at least one of R1, R2, R3 or R4 comprises an NH 2 moiety and at least one of R1, R2, R3 or R4 comprises one COOH moiety. Also provided is a method of preparing compounds of formula (I), and pharmaceutical compositions comprising the compounds. The novel compounds act as modulators of metabotropic glutamate receptors and, as such, are useful in treating diseases of the central nervous system related to the metabotropic glutamate receptor system.

  本发明涉及一种具有治疗活性的巴比妥酸的新型氨基、羧基、烷基衍生物，其化学式为(I)，其中R1、R2、R3或R4中至少有一个包含一个NH2基团，而R1、R2、R3或R4中至少有一个包含一个COOH基团。本发明还提供了一种制备化合物(I)的方法，以及包含该化合物的制药组合物。这些新型化合物作为代谢型谷氨酸受体调节剂，因此在治疗与代谢型谷氨酸受体系统相关的中枢神经系统疾病方面具有用途。
• Novel aminoindanes
  申请人：——

  公开号：US20040152670A1

  公开（公告）日：2004-08-05

  The present invention relates to therapeutically active novel aminoindanes of formula (I). Also provided is a method of preparing compounds of formula (I), and pharmaceutical compositions comprising the compounds. The novel compounds act as modulators of metabotropic glutamate receptors and, as such, are useful in treating diseases of the central nervous system related to the metabotropic glutamate receptor system.

  本发明涉及公式（I）的治疗活性新型氨基茚烷。还提供了制备公式（I）化合物的方法，以及包含该化合物的制药组合物。这些新型化合物作为代谢型谷氨酸受体的调节剂，因此在治疗与代谢型谷氨酸受体系统有关的中枢神经系统疾病方面是有用的。